




INNOCARE

诺诚健华



InnoCare Pharma – Interim Results

August 2021

Disclaimer


These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subsidiaries in any jurisdiction. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

The information or opinions contained in these materials has not been independently verified. No representation or warranty, whether expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information and opinions contained in these materials are provided as of the date of the presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. The Company, any of its affiliates, directors, supervisors, senior managers, officers, employees, advisers and their respective representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from or in reliance upon any information contained or presented in or derived from these materials or otherwise arising in connection with these materials.

These materials contain statements that reflect the Company’s current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company’s operations and businesses and on factors beyond the Company’s control, and are subject to significant risks and uncertainties, and, accordingly, the actual results may differ materially from these forward-looking statements. You should not place undue reliance on any of such forward-looking information. The Company assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that emerge subsequent to such dates.

To Become
a **Global Biopharmaceutical Leader**
that Develops and Delivers
Innovative Therapies for Patients Worldwide

Oncology



Autoimmune

Our Therapeutic Focus

1 Experienced founders and strong management team with an excellent track record

2 Fully integrated biopharmaceutical platform with robust in-house R&D capabilities

3 Proven track record in clinical development, business development and commercialization

4 Strategically focused pipeline of potential best/first-in-class targeted therapies

- Potential best-in-class BTKi Orelabrutinib launched in China
- Orelabrutinib in global Phase II trial for MS and partnered with Biogen, also in phase II for SLE and ITP
- In-licensed Tafasitamab – best available therapy for r/r DLBCL
- Second-generation FGFR & TRK inhibitors for solid tumors
- Abundant early stage NMEs including BCL-2, SHP-2, KRAS, TYK2 inhibitors, and E-3 ligase

5 Culture of innovation, efficiency, and excellence

Major Achievements in the Period of Jan – Aug 2021

Commercialization

- Orelabrutinib reported sales of **RMB101 million** in 1H2021
- Rapid Market Penetration
- Commercial team expansion
- NRDL process initiated

Business Development

- **Out-licensing:** Orelabrutinib in MS with Biogen
- **In-licensing:** Tafasitamab in hematology and oncology with Incyte

Research & Development

- 7 Clinical stage assets
- 5 Registrational trials ongoing
- 4 in-house developed NMEs disclosed
- 3 Biological molecules internalized

Capital Market

- Kicked off **STAR Board** Listing application process
- Raised approximately **US\$393 million** through a new shares placement with **Hillhouse and Vivo** in Feb 2021

Production Capacity

- Started tech-transfer of Orelabrutinib production in Guangzhou plant
- Planning construction of Beijing biological drug R&D and production facility

Talent Expansion

- **CMO** - Dr. Sean Zhang
- **COO** - Dr. Nan Gao
- **Biology VP** - Dr. Davy Ouyang
- Staff expanded to 600+

Commercialization

Strong Uptake of Core Product - Orelabrutinib

宜诺凯



■ Indications:

- R/R Mantle Cell Lymphoma (“MCL”)
- R/R Chronic Lymphocytic Leukemia/Small Cell leukemia (“CLL/SLL”)

■ Records Setting:

- From FPI to NDA filing: 1.5 years
- From FPI to NDA approval: 2.5 years

- Sales reached **RMB101M** in less than six months
- An experienced in-house team effectively penetrated the market:
 - Penetrated 230+ Cities
 - Covered 500+ Hospitals
 - Educated 4,000+ Doctors
- Recommended use by CSCO Diagnosis and Treatment Guidelines for r/r CLL/SLL, r/r MCL, r/r DLBCL and PCNSL
- Included in 19 local government supported/guided commercial insurance
- Actively pursuing Orelabrutinib’s inclusion in NRDL
- Well prepared for post-NRDL era:
 - Expanding sales and marketing team
 - Finishing provincial listing (挂网) and working on hospital entry (进院) process
 - Clinical trials in expanding indications

Business Development

Out-licensed Orelabrutinib in MS with Biogen

A CNS Penetrant BTKi for the Potential Treatment of MS

Royalties

Tiered
Low to High
teens on
potential future
net sales

Milestone

Potential
US\$812.5 million

Upfront

Payment
US\$125 million



Oncology
*Exclusive
worldwide
rights*

MS
*Exclusive
worldwide
rights*

Auto-immune
*Certain
diseases in
Greater China*

Auto-immune
*Certain
diseases
outside China*

A Significant Milestone for InnoCare

- A jump-start step to globalization: out-licensed self-developed molecule to a global pharmaceutical company, the largest small molecule deal in terms of upfront payment
- A major validation of Orelabrutinib's potential for MS and auto-immune disease treatment
- Well positioned to maximize Orelabrutinib's value in MS with the global leading player partnership
- A milestone deal that demonstrated our BD capability and will facilitate our future BD opportunities
- Additional financial prowess and operational flexibility for future growth

Tafacitamab - A differentiated CD-19 Antibody

Comprehensive Clinical Program

- Approved in the U.S. and Europe for r/r DLBCL
- In Phase III studies for 1L DLBCL, r/r FL and more by Incyte/MorphoSys
- Aggressively pursuing the best possible regulatory approval path in Greater China

Mutually Beneficial Deal Terms

- Exclusive Rights in the Greater China
- Upfront US\$35m
- Potential Milestone US\$82.5m
- Tiered Royalties




Strategically important for InnoCare

- MONJUVI (Tafasitamab-cxix) in combination with lenalidomide is the **first and only FDA-approved** treatment for 2nd line **DLBCL**
- Tafasitamab offers numerous possibility and flexibility in combination **with Orelabrutinib** and our other assets for the treatment of B-cell malignancy
- An important asset that will facilitate our strategy of becoming a leading player in hema-oncology in China
- Another demonstration of our BD capability and efficiency

Business Development

Tafasitamab: Best r/r DLBCL Drug in Market Today

Substantial DLBCL Market Size in China



Source: Frost & Sullivan Analysis

Best-in-Class CD19 antibody

- Engineered Fc domain and better ADCC and ADCP
- Solid data in the Phase II L-MIND study in r/r DLBCL
- Benign safety profile

Competitive Landscape: Selected Novel Therapy in r/r DLBCL

Company	Target	Therapy	Phase	ORR (%)	CR (%)	mDOR (m)	mPFS (m)	mOS (m)
Incyte/InnoCare	CD19	Tafasitamab + Lenalidomide	Approved ex-China	57.5	40	43.9	11.6	33.5
ADC Therapeutics	CD19 ADC	Loncastuximab tesirine	II	59	41	4.8	5.5	11.6
Roche	CD79b ADC	Polatuzumab vedotin + BR vs BR	II	45 vs 18	40 vs 18	12.6 vs 7.7	9.5 vs 3.7	12.4 vs 4.7
Amgen/Beigene	CD19/CD3	Blinatumomab	II	43	19	11.6	3.7	5.0
Regeneron/Zai Lab	CD20/CD3	Mosunetuzumab	Ib	35	19	N/A	N/A	N/A
Roche	CD20/CD3	Glofitamab	Ib	38	31	N/A	N/A	N/A
Others	BCL2	Venetoclax	I	18	12	N/A	1.0	8.0

Source: Frost & Sullivan Analysis


Note 1: antibody-dependent cell-mediated cytotoxicity (ADCC)

Note 2: antibody-dependent cellular phagocytosis (ADCP)

Note 3: autologous stem cell transplant (ASCT)

Research and & Development






























Product Pipeline – Liquid Cancer



 Registrational trials  Clinical Stage  Pre-clinical Stage

Research and & Development

Product Pipeline – Solid Tumors and Autoimmune Diseases

	Drug	Target	Indication(s)	Worldwide Rights	Pre-clinical Development	IND	Phase I	Phase II	Phase III	Launched
Solid Tumors	ICP-192/ Gunagratinib	pan-FGFR	Cholangiocarcinoma							
			Urothelial cancer							
			pan-FGFR (basket)		US Development Status 					
	ICP-105	FGFR4	HCC							
	ICP-723	pan-TRK	NTRK fusion-positive cancers							
	ICP-033	VEGFR, DDR1	Solid tumors							
	ICP-915	KRAS	Solid tumors		IND expected in second half of 2022 					
	ICP-189	SHP2	Solid tumors		IND accepted in July 2021 					
ICP-B03	IL-15	Solid tumors		IND expected in second half of 2022 						
Auto-immune diseases	BTK	ICP-022/ Orelabrutinib	SLE							
			MS		Global Development Status  					
			ITP							
	ICP-332	TYK2 – JH1	Autoimmune diseases							
	ICP-488	TYK2 – JH2	Autoimmune diseases		IND expected in second half of 2021 					
	ICP-490	E3 ligase	Autoimmune diseases		IND expected in first half of 2022 					

Next 12 Months – A Busy and Eventful Period

Orelabrutinib

- Submit r/r WM NDA in 1H2022
- Submit r/r MZL NDA in 1H2022
- Submit r/r MCL NDA in U.S. in 2H2022
- Finish SLE Phase II trial publish data in 1Q2022
- Initiate ITP patient enrollment in 2H2021
- Complete patient enrollment for MS in mid 2022

Capital Market

- STAR Board Listing 1H2022

Facilities

- Start Orelabrutinib in-house production in 1H2022
- Start the construction of Beijing R&D center & large molecule facility

Other Clinical Assets


- **ICP-192**
 - Initiate iCCA registrational trial
 - Complete the Phase I clinical study in the U.S.
- **ICP-723**
 - Start a NTRK mutation-based registrational trial
 - Initiate patient enrollment in the U.S.
- **ICP-332**: complete Phase I trial
- **Tafasitamab**: approval in HK/Big Bay Area; Initiate registrational trial in China
- **Have 2-3 NMEs into phase I**
- **Submit 3-4 INDs, Select 2-3 new PCCs**



Key Financials Updates for 1H2021


Revenue

(RMB mm)




Research and Development Costs

(RMB mm)




Loss for the Period

(RMB mm)



Cash and Cash Equivalents

(RMB mm)



¹ Cash balance = investments measured at fair value investments, cash and bank balance.
 Net cash = cash balance – convertible loan – loans and borrowings – loans from a related party

科学驱动创新 患者所需为本

Science Drives Innovation for the Benefit of Patients
